Evaluation of a novel vaccine delivery and expression platform-Plasmid Launched Live Attenuated Viral Vaccine (PLLAV) (RABVAXDOSE)

Prof J.Neyts and his team is interested in

*encapsulation of model pDNA into lipid nanoparticles

*evaluate pDNA LNPs at a dose of 2.5µg/mice using intramuscular and subcutaneous injections

*evaluate the best performing formulations in hamster and pigs

Experimental plan:

use PNI's proprietary lipid compositions to screen processing conditions for encapsulation of model pNA, selection criteria: particle size<170 nm, PDI<0.2, encapsulation efficiency >80%

prepare a fresh batch of pDNA LNPs, evaluate particle characteristics.

Objective 1-Formulation screening

1 Screen PNI's lipid compositions for encapsulation of model pDNA

2 Evaluate particle characteristics and select conditions that meet selection criteria

3 Concentrate select formulations to a target concentration of 100µg/mL

4 All formulations will be prepared on NanoAssemblr platform and evaluated for size, polydispersity using Malvern Zetasizer.pDNA concentration and encapsulation will be evaluated using plate-based assy using PicoGreen reagent